| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | 10-15 scrolls | Preferred |
| Tissue slides (FFPE) | Slides | 10-15 slides | Preferred |
| Whole blood | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Bone marrow | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Buccal swab | Buccal swab kit | 4 swabs | Preferred |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | 1 block | Preferred |
| Saliva | Oragene saliva collection tube | 2 tubes | Preferred |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. For malignant conditions, the disease-involved sample must contain a minimum of 20% tumor or disease content for single-nucleotide and small insertion-deletion variant resolution, and 60% tumor or disease content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content.
If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and an adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.
For questions, please call the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory at (614) 722-5321 and ask to speak with a laboratory genetic counselor.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | 10-15 scrolls | Preferred |
| Tissue slides (FFPE) | Slides | 10-15 slides | Preferred |
| Whole blood | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Bone marrow | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Buccal swab | Buccal swab kit | 4 swabs | Preferred |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | 1 block | Preferred |
| Saliva | Oragene saliva collection tube | 2 tubes | Preferred |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 30 mg |
| Tissue (Snap-frozen) | Cryogenic tube | 30 mg |
| Tissue scrolls (FFPE) | Sterile container | 5-10 microns thick |
| Tissue slides (FFPE) | Slides | 5-10 microns thick |
| Whole blood | 4 mL Purple tube (EDTA) | 1 mL |
| Bone marrow | 4 mL Purple tube (EDTA) | 1 mL |
| Buccal swab | Buccal swab kit | 2 swabs |
| OCT-embedded tissue | Tissue cassette | 30 mg |
| OCT-embedded tissue | Cryogenic tube | 30 mg |
| Paraffin embedded tissue | Paraffin block | 1 block |
| Saliva | Oragene saliva collection tube | 1 tube |
| Tissue (Fresh) | Tissue culture transport media | 30 mg |
| Tissue (Fresh) | Sterile container with saline | 30 mg |
This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. For malignant conditions, the disease-involved sample must contain a minimum of 20% tumor or disease content for single-nucleotide and small insertion-deletion variant resolution, and 60% tumor or disease content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content.
If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and an adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.
For questions, please call the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory at (614) 722-5321 and ask to speak with a laboratory genetic counselor.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | 10-15 scrolls | Preferred |
| Tissue slides (FFPE) | Slides | 10-15 slides | Preferred |
| Whole blood | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Bone marrow | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Buccal swab | Buccal swab kit | 4 swabs | Preferred |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | 1 block | Preferred |
| Saliva | Oragene saliva collection tube | 2 tubes | Preferred |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 30 mg |
| Tissue (Snap-frozen) | Cryogenic tube | 30 mg |
| Tissue scrolls (FFPE) | Sterile container | 5-10 microns thick |
| Tissue slides (FFPE) | Slides | 5-10 microns thick |
| Whole blood | 4 mL Purple tube (EDTA) | 1 mL |
| Bone marrow | 4 mL Purple tube (EDTA) | 1 mL |
| Buccal swab | Buccal swab kit | 2 swabs |
| OCT-embedded tissue | Tissue cassette | 30 mg |
| OCT-embedded tissue | Cryogenic tube | 30 mg |
| Paraffin embedded tissue | Paraffin block | 1 block |
| Saliva | Oragene saliva collection tube | 1 tube |
| Tissue (Fresh) | Tissue culture transport media | 30 mg |
| Tissue (Fresh) | Sterile container with saline | 30 mg |
This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. For malignant conditions, the disease-involved sample must contain a minimum of 20% tumor or disease content for single-nucleotide and small insertion-deletion variant resolution, and 60% tumor or disease content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content.
If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and an adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.
For questions, please call the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory at (614) 722-5321 and ask to speak with a laboratory genetic counselor.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
| Outpatient Requirements |
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | 10-15 scrolls | Preferred |
| Tissue slides (FFPE) | Slides | 10-15 slides | Preferred |
| Whole blood | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Bone marrow | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Buccal swab | Buccal swab kit | 4 swabs | Preferred |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | 1 block | Preferred |
| Saliva | Oragene saliva collection tube | 2 tubes | Preferred |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. For malignant conditions, the disease-involved sample must contain a minimum of 20% tumor or disease content for single-nucleotide and small insertion-deletion variant resolution, and 60% tumor or disease content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content.
If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and an adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.
For questions, please call the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory at (614) 722-5321 and ask to speak with a laboratory genetic counselor.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
| Inpatient Requirements |
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | 10-15 scrolls | Preferred |
| Tissue slides (FFPE) | Slides | 10-15 slides | Preferred |
| Whole blood | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Bone marrow | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Buccal swab | Buccal swab kit | 4 swabs | Preferred |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | 1 block | Preferred |
| Saliva | Oragene saliva collection tube | 2 tubes | Preferred |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 30 mg |
| Tissue (Snap-frozen) | Cryogenic tube | 30 mg |
| Tissue scrolls (FFPE) | Sterile container | 5-10 microns thick |
| Tissue slides (FFPE) | Slides | 5-10 microns thick |
| Whole blood | 4 mL Purple tube (EDTA) | 1 mL |
| Bone marrow | 4 mL Purple tube (EDTA) | 1 mL |
| Buccal swab | Buccal swab kit | 2 swabs |
| OCT-embedded tissue | Tissue cassette | 30 mg |
| OCT-embedded tissue | Cryogenic tube | 30 mg |
| Paraffin embedded tissue | Paraffin block | 1 block |
| Saliva | Oragene saliva collection tube | 1 tube |
| Tissue (Fresh) | Tissue culture transport media | 30 mg |
| Tissue (Fresh) | Sterile container with saline | 30 mg |
This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. For malignant conditions, the disease-involved sample must contain a minimum of 20% tumor or disease content for single-nucleotide and small insertion-deletion variant resolution, and 60% tumor or disease content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content.
If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and an adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.
For questions, please call the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory at (614) 722-5321 and ask to speak with a laboratory genetic counselor.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
| Overview/Billing |
| Interpretation |
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
| NCH Lab Only |
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | 10-15 scrolls | Preferred |
| Tissue slides (FFPE) | Slides | 10-15 slides | Preferred |
| Whole blood | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Bone marrow | 4 mL Purple tube (EDTA) | 4 mL | Preferred |
| Buccal swab | Buccal swab kit | 4 swabs | Preferred |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | 1 block | Preferred |
| Saliva | Oragene saliva collection tube | 2 tubes | Preferred |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 30 mg |
| Tissue (Snap-frozen) | Cryogenic tube | 30 mg |
| Tissue scrolls (FFPE) | Sterile container | 5-10 microns thick |
| Tissue slides (FFPE) | Slides | 5-10 microns thick |
| Whole blood | 4 mL Purple tube (EDTA) | 1 mL |
| Bone marrow | 4 mL Purple tube (EDTA) | 1 mL |
| Buccal swab | Buccal swab kit | 2 swabs |
| OCT-embedded tissue | Tissue cassette | 30 mg |
| OCT-embedded tissue | Cryogenic tube | 30 mg |
| Paraffin embedded tissue | Paraffin block | 1 block |
| Saliva | Oragene saliva collection tube | 1 tube |
| Tissue (Fresh) | Tissue culture transport media | 30 mg |
| Tissue (Fresh) | Sterile container with saline | 30 mg |
This test requires submission of both a disease-involved sample (somatic sample) and non-disease-involved sample (germline comparator sample) from the patient. For malignant conditions, the disease-involved sample must contain a minimum of 20% tumor or disease content for single-nucleotide and small insertion-deletion variant resolution, and 60% tumor or disease content for sensitive resolution of copy number variation (CNV) and loss of heterozygosity (LOH) to enable interpretation and reporting. Sensitivity in calling CNV and LOH will be limited, and at times, assay resolution of these events will preclude interpretation and reporting of CNV and LOH, if the submitted specimen contains less than 60% disease-content.
If submitting a tissue scroll or slide specimen, please submit 10-15 FFPE scrolls or slides (5-10 microns thick) and an adjacent H&E slide, or use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.
For questions, please call the NCH Institute for Genomic Medicine (IGM) Clinical Laboratory at (614) 722-5321 and ask to speak with a laboratory genetic counselor.
This test is intended for a patient with known or suspected cancer, hematologic disease, or somatic disorders (e.g. somatic overgrowth, vascular malformation, or other mosaic disease). Genomic characterization of a tumor or disease-involved tissue can aid in diagnosis, prognosis, and medical management, such as making treatment decisions and evaluating eligibility for targeted therapies and clinical trials. This test can also identify germline disease predisposition.
This test consists of paired exome sequencing analysis on both disease-involved and non-disease involved samples. See attached list of germline and somatic genes reviewed during interpretation. In addition, CNV, LOH and small variants/indels will be reported if identified.
The presence of pathogenic variant(s) confined to disease-involved tissue(s) can be found in malignancies/somatic diseases, and these variants are described as somatic in origin. Sometimes, a pathogenic variant is also detected in the patient’s germline sample, which indicates that the variant is germline in origin and occurs throughout all cells in the body. Germline variants can be associated with hereditary predisposition to disease.
